This is a randomised two arm study, comparing artemether-lumefantrine 3 days and 5 days treatment. Patients will be randomised in blocks of ten to one of the two treatment arms. The standard regimen is twice daily for three days with a delay of at least eight hours between the first and second doses. A single of primaquine will be given to all patients on the first day of treatment for gametocytocidal activity. The initial treatment will be given under supervision, all other subsequent doses will be given to the patient to the taken at home. Patients will be followed up for nine visits over forty two days.
* The study will be conducted in 6 village health centres in the Mon and Kayin states * The patient or parent/guardian (in case of minor or under aged) must personally sign and date the latest approved version of the informed consent form before any study specific procedures are performed * A case record form will be completed for each patient documenting symptoms prior to clinic attendance, concomitant illness, drug history. Height, weight, vital signs and physical examination findings will be recorded. * At enrolment (D0) all patients will have the following samples taken: * Repeat parasite count (thick and thin films). Treatment should be started without waiting for the result. * Filter paper blood blots (3 dots on Whatman 3MM filter paper approx 180-300 µL blood) for parasite genotyping (MSP1, MSP2, GLURP in case of recurrence during follow-up) * Haemoglobin * Laboratory procedures * Slide microscopy: Thick and thin blood films stained with Giemsa will be read and counts expressed as the number of parasites per 500 white blood cells * Molecular studies: The samples will be used to detect asexual parasites (blood smear, sensitive PCR), parasite population structure (Sequenom genotyping and sequencing), gametocytes (microscopy). The samples will be stored in a cool box and kept maximum 5 days in the field and will be transported to the local laboratory for processing. Plasma and buffy coat will be separated, frozen and stored. The frozen packed red cells will be transported to the molecular laboratory at MORU, Bangkok, Thailand, for sample processing (DNA extraction, quantitative PCRs).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
150
One tablet contains 20mg artemether and 120mg lumefantrine. The standard regimen is twice daily for 3 days with a delay of at least 8 hours between the first and second dose. It is dosed by weight categories. One gram of fish oil will be given to half of the participants in the 3 days arm.
One tablet contains 20mg artemether and 120mg lumefantrine. The experiment regimen is twice daily for 5 days with a delay of at least 8 hours between the first and second dose. It is dosed by weight categories. One gram of fish oil will be given to half of the participants in the 5 days arm.
Medical Action Myanmar
Yangon, Burma
proportion of patients with detectable parasitaemia
Assessed by sensitive PCR on days 5 and 7 after treatment
Time frame: On day 5 and day 7
Parasitaemia clearance time
Assessed by sensitive PCR on D3 in the 3 day arm and D5 in the 5 day arm
Time frame: On day 3 and Day 5
Gametocyte carriage rates
Time frame: Day 7
artemether-lumefantrine tolerability
Tolerability of artemether-lumefantrine will be assessed by comparing the proportion of patients with anorexia, nausea, vomiting, abdominal pain and other symptoms of administration between the intervention arm and the control arm
Time frame: 5 days
Comparison of effectiveness
Comparison of effectiveness uncorrected and corrected will be assessed by PCR genotyping
Time frame: Day 42
concentrations of lumefantrine
Time frame: Day 7
Haematological recovery rate
Assessed by comparing hemoglobin between baseline and after treatment at day 28
Time frame: Day 28
Incidence of vivax malaria relapses
Assessed by the microscopist find malaria smear positive within the follow up period
Time frame: 42 days
Comparison of addition of food supplement (fish oil)
Assessed by comparing lumefantrine concentration on day 7 and proportion of patients with detectable parasitaemia by qPCR
Time frame: day 3 to day 21
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.